Indeed, despite over 95% of pancreatic cancers harbor oncogenicKRAS mutations, and the ERK1/2 signaling pathway is always involved in this process, other gene mutations, such asTP53 andSMAD4 which often exist in PDAC patients, may also have a promoting or inhibiting effect on tumors by regulating the activation of the ERK1/2 signaling pathway [29,30] . The gene discussed is MAPK3; the disease is familial pancreatic carcinoma.